{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-000015","form_type":"8-K","ticker":null,"cik":"0001657312","company_name":"Verona Pharma plc","filed_at":"2024-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.000459+00:00","generated_at":"2026-06-07T05:20:04.139069+00:00","sec_items":["1.01","1.02","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verona Pharma secures up to $400M debt facility for planned launch of ensifentrine","bullets":["Drew $50M at closing; additional $100M available upon FDA approval of ensifentrine (PDUFA June 26, 2024).","Up to $150M in two tranches subject to net sales milestones; $100M discretionary for strategic initiatives.","53-month interest-only period, then 7-month amortization; final payment fee 2.50%-3.50%.","Replaces existing $150M facility with Oxford; $20M outstanding repaid plus prepayment costs.","Non-dilutive capital to support commercial launch; lenders: Oxford Finance and Hercules Capital (HTGC)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-000015","json":"https://secwatch.observer/filing/0001104659-24-000015.json","markdown":"https://secwatch.observer/filing/0001104659-24-000015.md","text":"https://secwatch.observer/filing/0001104659-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1657312/000110465924000015/0001104659-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1657312/000110465924000015/tm2333838d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:20:04.139069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c641d6bac547c55d3f6b4dc334e2c773789b8e4","claim":"Verona Pharma plc incurred term loan of $400.0 million with Oxford Finance LLC and funds managed by Oxford and Hercules Capital, Inc. at (a) the greater of (i) the 1-Month CME Term SOFR reference rate...and (ii) 5.34% maturing December 1, 2028.","evidence_excerpt":"On December 27, 2023 (the “Effective Date”), Verona Pharma, Inc. (the “Borrower”), a wholly-owned subsidiary of Verona Pharma plc (the “Company”), entered into a term loan facility of up to $400.0 million (the “Term Loan”), consisting of a term loan advance in an aggregate amount of $50.0 million funded on the Effective Date (the “Term A Loan”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1657312/000110465924000015/0001104659-24-000015-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$400.0 million"},{"label":"Counterparty","value":"Oxford Finance LLC and funds managed by Oxford and Hercules Capital, Inc."},{"label":"Rate","value":"(a) the greater of (i) the 1-Month CME Term SOFR reference rate...and (ii) 5.34%"},{"label":"Maturity","value":"December 1, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"ecd7e82844c0e9b954e45efc8cc19b90b87e6a09","claim":"Verona Pharma plc entered into Loan Agreement with Oxford Finance LLC, as collateral agent, and funds managed by Oxford and Hercules Capital, Inc. valued at up to $400.0 million (effective 2023-12-27).","evidence_excerpt":"On December 27, 2023 (the “Effective Date”), Verona Pharma, Inc. (the “Borrower”), a wholly-owned subsidiary of Verona Pharma plc (the “Company”), entered into a term loan facility of up to $400.0 million (the “Term Loan”), consisting of a term loan advance in an aggregate amount of $50.0 million funded on the Effective Date (the “Term A Loan”), a term loan advance available subject to certain terms and conditions in an aggregate amount of $100.0 million (the “Term B Loan”), a term loan advance available subject to certain terms and conditions in an aggregate amount of $75.0 million (the “Term C Loan”), a term loan advance available subject to certain terms and conditions in an aggregate amount of $75.0 million (the “Term D Loan”) and a term loan advance available in the sole discretion of the lenders and subject to certain terms and conditions in an aggregate amount of $100.0 million (the “Term E Loan”), with Oxford Finance LLC, a Delaware limited liability company, as collateral agen","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1657312/000110465924000015/0001104659-24-000015-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oxford Finance LLC, as collateral agent, and funds managed by Oxford and Hercules Capital, Inc."},{"label":"Value","value":"up to $400.0 million"},{"label":"Effective","value":"2023-12-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}